View Financial HealthChina Health Technology Group Holding 配当と自社株買い配当金 基準チェック /06China Health Technology Group Holding配当金を支払った記録がありません。主要情報n/a配当利回り-21.8%バイバック利回り総株主利回り-21.8%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Jul 11China Health Technology Group Holding Company Limited Announces Company Secretary Changes, Effective July 9, 2026China Health Technology Group Holding Company Limited announced that the Board resolved to change the position of the company secretary of the Company from Mr. Chan Ngai Fan to Mr. Chow Yun Cheung with effect from July 9, 2026. Following the above change of the Company Secretary, Mr. Chan Ngai Fan ceased to act as an authorised representative of the Company under Rule 3.05 of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited with effect from July 9, 2026; and Mr. Chow Yun Cheung has been appointed as the Authorised Representative with effect from July 9, 2026. Mr. Chow Yun Cheung is a member of the Hong Kong Institute of Certified Public Accountants. Mr. Chow Yun Cheung obtained a bachelor’s degree in business administration from the Chinese University of Hong Kong and has over 20 years of experience in the related fields of accounting, corporate finance and compliance.お知らせ • Mar 28China Health Technology Group Holding Company Limited has filed a Follow-on Equity Offering in the amount of HKD 51.46211 million.China Health Technology Group Holding Company Limited has filed a Follow-on Equity Offering in the amount of HKD 51.46211 million. Security Name: Shares Security Type: Common Stock Securities Offered: 205,848,440 Price\Range: HKD 0.25 Transaction Features: Rights Offeringお知らせ • Feb 12China Health Technology Group Holding Company Limited to Report First Half, 2026 Results on Feb 27, 2026China Health Technology Group Holding Company Limited announced that they will report first half, 2026 results on Feb 27, 2026お知らせ • Dec 10China Health Technology Group Holding Company Limited, Annual General Meeting, Dec 31, 2025China Health Technology Group Holding Company Limited, Annual General Meeting, Dec 31, 2025, at 11:00 China Standard Time. Location: unit no. 2808-10, 28th floor of west tower shun tak centre, nos. 168-200 connaught road central, Hong Kongお知らせ • Sep 18China Health Technology Group Holding Company Limited to Report Fiscal Year 2025 Results on Sep 30, 2025China Health Technology Group Holding Company Limited announced that they will report fiscal year 2025 results at 4:00 PM, China Standard Time on Sep 30, 2025お知らせ • Aug 01China Health Technology Group Holding Company Limited has completed a Follow-on Equity Offering in the amount of HKD 4.76 million.China Health Technology Group Holding Company Limited has completed a Follow-on Equity Offering in the amount of HKD 4.76 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 17,000,000 Price\Range: HKD 0.28 Discount Per Security: HKD 0.0042 Transaction Features: Subsequent Direct Listingお知らせ • Jul 22China Health Technology Group Holding Company Limited has filed a Follow-on Equity Offering in the amount of HKD 4.76 million.China Health Technology Group Holding Company Limited has filed a Follow-on Equity Offering in the amount of HKD 4.76 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 17,000,000 Price\Range: HKD 0.28 Discount Per Security: HKD 0.0042 Transaction Features: Subsequent Direct Listingお知らせ • Mar 14China Health Technology Group Holding Company Limited Announces Appointment of Li Zhiliang as Chief Executive Officer of Subsidiary, Genmao (Shenzhen) Biotechnology Co., LtdChina Health Technology Group Holding Company Limited board of directors announced that Mr. Li Zhiliang ("Mr. Li") has been appointed as the chief executive officer of Genmao (Shenzhen) Biotechnology Co. Ltd. ("Genmao Biotech"), a wholly-owned subsidiary of the Company, responsible for the strategic planning, business expansion, and daily operational management of the company with effect from 12 March 2025. Mr. Li is a senior expert in the acer truncatum industry. He has been engaged in the entire industrial chain of acer truncatum for 22 years and has rich management experience. Mr. Li has been deeply involved in the formulation of the National Standard for Acer Truncatum Bunge Seed Oil (GB/T37748-2019) and has participated in the implementation of various national-level acer truncatum industry integration projects. The Board believes that Mr. Li's professional qualifications, industry resources and management capabilities are highly consistent with Genmao Biotech's strategic direction of focusing on the development of the entire industrial chain of acer truncatum. Such appointment will significantly enhance the Company's technological barriers and brand influence in the functional food and oil market, creating long-term value for shareholders.お知らせ • Feb 18China Health Technology Group Holding Company Limited to Report First Half, 2025 Results on Feb 28, 2025China Health Technology Group Holding Company Limited announced that they will report first half, 2025 results on Feb 28, 2025お知らせ • Dec 05China Health Technology Group Holding Company Limited, Annual General Meeting, Dec 30, 2024China Health Technology Group Holding Company Limited, Annual General Meeting, Dec 30, 2024, at 15:30 China Standard Time. Location: unit no. 2808-10 on 28th floor, west tower shun tak centre, nos. 168-200 connaught road central, Hong Kongお知らせ • Sep 17China Health Technology Group Holding Company Limited to Report Fiscal Year 2024 Results on Sep 30, 2024China Health Technology Group Holding Company Limited announced that they will report fiscal year 2024 results at 9:30 AM, China Standard Time on Sep 30, 2024お知らせ • Feb 20China Health Technology Group Holding Company Limited to Report Second Half, 2023 Results on Feb 29, 2024China Health Technology Group Holding Company Limited announced that they will report second half, 2023 results on Feb 29, 2024お知らせ • Feb 01China Health Technology Group Holding Company Limited Announces Executive ChangesThe board of directors of China Health Technology Group Holding Company Limited announced that Mr. Ngai Tsz Hin Michael ("Mr. Ngai") has tendered his resignation as the joint company secretary of the Company (the "Company Secretary") and ceased to act as an authorised representative of the Company (the "Authorised Representative") under Rule 3.05 of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") with effect from 31 January 2024. The Board also announced that, following the resignation of Mr. Ngai, Mr. Chan Ngai Fan ("Mr. Chan"), the existing company secretary of the Company, will continue to act as the Company Secretary and Mr. Chan has been appointed as the Authorised Representative with effect from 31 January 2024. Following the change, the Authorised Representatives are Professor Fei Phillip and Mr. Chan.お知らせ • Jan 30China Health Technology Group Holding Company Limited Announces Resignation of Chan Wai Lung as an Executive DirectorChina Health Technology Group Holding Company Limited announced that Mr. Chan Wai Lung has resigned as an executive Director with effect from 29 January 2024 due to his other business engagements requiring more of time.お知らせ • Nov 22+ 1 more updateChina Bozza Development Holdings Limited Announces CEO ChangesChina Bozza Development Holdings Limited announced Following the retirement of Mr. Li Wenjun as an executive Director, the Board announced that Mr. Li has resigned as the chief executive officer of the Company with effect from 21 November 2023. The Board announced that Mr. Chan Wai Lung ("Mr. Chan") has been appointed as the Chief Executive Officer with effect from 21 November 2023. Mr. Chan Wai Lung, aged 42, was appointed as an independent non-executive Director on 19 May 2023 and re-designated as an executive Director on 14 August 2023. Mr. Chan has years of experience in business planning and development. Mr. Chan has been an executive Director of Finsoft Financial Investment Holdings Limited since June 2017 and has been the Chief Executive Officer of Finsoft since December 2021. Mr. Chan has been a director of Draco International Investment (Holdings) Limited (specialising in designing corporate structures) since July 2013, and a director of Draco Human Resources Management Limited since November 2016. Mr. Chan was a non-executive director of Noble Engineering Group Holdings Limited from August 2018 to January 2020. Mr. Chan was appointed as a business development consultant by the Management Committee of the Haining Economic Development Zone, Zhejiang Province, the PRC in April 2017. In October 2017, he obtained his Honorary Doctorate in Business Administration from Sabi University. In November 2019, Mr. Chan completed a postdoctoral research project at California State University Monterey Bay.お知らせ • Oct 31China Bozza Development Holdings Limited, Annual General Meeting, Nov 21, 2023China Bozza Development Holdings Limited, Annual General Meeting, Nov 21, 2023, at 15:30 China Standard Time. Location: Unit No. 280810 on 28th Floor of West Tower Shun Tak Centre Nos. 168200 Connaught Road Central, Hong Kong Hong Kong Agenda: To receive, consider and adopt the audited financial statements, the report of the directors (the "Directors") and the report of the independent auditor for the eighteen months ended 30 June 2021; to receive, consider and adopt the audited financial statements, the report of the Directors and the report of the independent auditor for the year ended 30 June 2022; to receive, consider and adopt the audited financial statements, the report of the Directors and the report of the independent auditor for the year ended 30 June 2023; and to consider other matters.お知らせ • Sep 22China Bozza Development Holdings Limited to Report Fiscal Year 2023 Results on Sep 30, 2023China Bozza Development Holdings Limited announced that they will report fiscal year 2023 results on Sep 30, 2023お知らせ • Sep 09China Bozza Development Holdings Limited (SEHK:1069) entered into equity sale and purchase agreement to acquire 52% stake in Liuba County Jiashisen Traditional Chinese Medicine Comprehensive Development Company Limited from Shaanxi Jiashisen Pharmaceutical Investment Company Limited for CNY 7.1 million.China Bozza Development Holdings Limited (SEHK:1069) entered into equity sale and purchase agreement to acquire 52% stake in Liuba County Jiashisen Traditional Chinese Medicine Comprehensive Development Company Limited from Shaanxi Jiashisen Pharmaceutical Investment Company Limited for CNY 7.1 million on August 16, 2023. Upon the Completion, China Bozza Development will hold 52% equity interest in Liuba County Jiashisen Traditional Chinese Medicine Comprehensive Development, which will become a non-wholly owned subsidiary of the China Bozza Development.お知らせ • Aug 17China Bozza Development Holdings Limited Announces Board ChangesThe board (the "Board") of directors (the "Director(s)") of China Bozza Development Holdings Limited (the "Company", and together with its subsidiaries, the "Group") announced that Mr. Chan Wai Lung ("Mr. Chan"), an independent non-executive Director, has been re-designated as an executive Director with effect from 14 August 2023. Mr. Chan Wai Lung, aged 42, was appointed as an independent non-executive Director on 19 May 2023. Mr. Chan has years of experience in business planning and development. Mr. Chan has been an executive Director of Finsoft Financial Investment Holdings Limited since June 2017 and has been the Chief Executive Officer of Finsoft since December 2021. Mr. Chan has been a director of Draco International Investment (Holdings) Limited (specialising in designing corporate structures) since July 2013, and a director of Draco Human Resources Management Limited since November 2016. Mr. Chan was a non-executive director of Noble Engineering Group Holdings Limited, from August 2018 to January 2020. Mr. Chan was appointed as a business development consultant by the Management Committee of the Haining Economic Development Zone, Zhejiang Province, the PRC in April 2017. In October 2017, he obtained his Honorary Doctorate in Business Administration from Sabi University. In November 2019, Mr. Chan completed a postdoctoral research project at California State University Monterey Bay. The Board also announced that (i) Mr. Chau Wing Nam ("Mr. Chau") has been appointed as an independent non-executive Director, the chairman of the audit committee of the Company (the "Audit Committee") and the chairman of the Remuneration Committee; and (ii) Ms. Bu Xue has been appointed as an independent non-executive Director and a member of each of the Audit Committee, the Remuneration Committee and the nomination committee of the Company (the "Nomination Committee") with effect from 14 August 2023. Mr. Chau Wing Nam, aged 35, obtained his Bachelor's degree in Accounting and Accounting Technologies from the Curtin University of Technology in August 2012. He has been a member of Hong Kong Institute of Certified Public Accountants since May 2017. He has over ten years of experience in auditing, accounting and corporate management and is currently responsible for corporate finance, mergers and acquisitions matters, investors relations, corporate governance as well as compliance affairs. Mr. Chau is currently a manager of Ample Capital Limited and is a licensed person registered under the Securities and Futures Ordinance to carry out Type 6 (advising on corporate finance) regulated activity. Mr. Chau is currently an independent non-executive director of K Group Holdings Limited since June 2022 and an independent non-executive director of Mobile Internet (China) Holdings Limited since February 2023. Ms. Bu Xue, aged 34, obtained her Bachelor's degree in Business Administration from Zhengzhou University of Aeronautics in July 2011. She has attained the accounting professional qualification issued by Ministry of Human Resources and Social Security and Ministry of Finance of the People's Republic of China since September 2020 and has attained the qualification of tax advisor issued by The China Certified Tax Agents Association since December 2022. She has over ten years of experience in marketing and business development. The Board also announced that, following the change in the composition of the Board and with effect from 14 August 2023: Mr. Liu Zhaoxiang ceased to be a member of the Audit Committee; Ms. Wong Hoi Ying ceased to be the chairman of the Nomination Committee and a member of each of the Audit Committee and the Remuneration Committee; Professor Fei Phillip ceased to be a member of each of the Remuneration Committee and Nomination Committee; Mr. Wang Yibin has been appointed as a member of the Nomination Committee; Mr. Guo Zhonglong has been appointed as the chairman of the Nomination Committee and a member of the Remuneration Committee and has been re-designated as a member of the Audit Committee; Mr. Chan ceased to be the chairman of the Remuneration Committee and a member of each of the Audit Committee and Nomination Committee; Mr. Chau has been appointed as the chairman of the Audit Committee and the chairman of the Remuneration Committee; and Ms. Bu has been appointed as a member of each of the Audit Committee, the Remuneration Committee and the Nomination Committee.決済の安定と成長配当データの取得安定した配当: CHBO.Fの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: CHBO.Fの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場China Health Technology Group Holding 配当利回り対市場CHBO.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (CHBO.F)n/a市場下位25% (US)1.3%市場トップ25% (US)4.0%業界平均 (Forestry)2.7%アナリスト予想 (CHBO.F) (最長3年)n/a注目すべき配当: CHBO.Fは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: CHBO.Fは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: CHBO.Fの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: CHBO.Fが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/16 04:34終値2026/03/19 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋China Health Technology Group Holding Company Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jul 11China Health Technology Group Holding Company Limited Announces Company Secretary Changes, Effective July 9, 2026China Health Technology Group Holding Company Limited announced that the Board resolved to change the position of the company secretary of the Company from Mr. Chan Ngai Fan to Mr. Chow Yun Cheung with effect from July 9, 2026. Following the above change of the Company Secretary, Mr. Chan Ngai Fan ceased to act as an authorised representative of the Company under Rule 3.05 of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited with effect from July 9, 2026; and Mr. Chow Yun Cheung has been appointed as the Authorised Representative with effect from July 9, 2026. Mr. Chow Yun Cheung is a member of the Hong Kong Institute of Certified Public Accountants. Mr. Chow Yun Cheung obtained a bachelor’s degree in business administration from the Chinese University of Hong Kong and has over 20 years of experience in the related fields of accounting, corporate finance and compliance.
お知らせ • Mar 28China Health Technology Group Holding Company Limited has filed a Follow-on Equity Offering in the amount of HKD 51.46211 million.China Health Technology Group Holding Company Limited has filed a Follow-on Equity Offering in the amount of HKD 51.46211 million. Security Name: Shares Security Type: Common Stock Securities Offered: 205,848,440 Price\Range: HKD 0.25 Transaction Features: Rights Offering
お知らせ • Feb 12China Health Technology Group Holding Company Limited to Report First Half, 2026 Results on Feb 27, 2026China Health Technology Group Holding Company Limited announced that they will report first half, 2026 results on Feb 27, 2026
お知らせ • Dec 10China Health Technology Group Holding Company Limited, Annual General Meeting, Dec 31, 2025China Health Technology Group Holding Company Limited, Annual General Meeting, Dec 31, 2025, at 11:00 China Standard Time. Location: unit no. 2808-10, 28th floor of west tower shun tak centre, nos. 168-200 connaught road central, Hong Kong
お知らせ • Sep 18China Health Technology Group Holding Company Limited to Report Fiscal Year 2025 Results on Sep 30, 2025China Health Technology Group Holding Company Limited announced that they will report fiscal year 2025 results at 4:00 PM, China Standard Time on Sep 30, 2025
お知らせ • Aug 01China Health Technology Group Holding Company Limited has completed a Follow-on Equity Offering in the amount of HKD 4.76 million.China Health Technology Group Holding Company Limited has completed a Follow-on Equity Offering in the amount of HKD 4.76 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 17,000,000 Price\Range: HKD 0.28 Discount Per Security: HKD 0.0042 Transaction Features: Subsequent Direct Listing
お知らせ • Jul 22China Health Technology Group Holding Company Limited has filed a Follow-on Equity Offering in the amount of HKD 4.76 million.China Health Technology Group Holding Company Limited has filed a Follow-on Equity Offering in the amount of HKD 4.76 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 17,000,000 Price\Range: HKD 0.28 Discount Per Security: HKD 0.0042 Transaction Features: Subsequent Direct Listing
お知らせ • Mar 14China Health Technology Group Holding Company Limited Announces Appointment of Li Zhiliang as Chief Executive Officer of Subsidiary, Genmao (Shenzhen) Biotechnology Co., LtdChina Health Technology Group Holding Company Limited board of directors announced that Mr. Li Zhiliang ("Mr. Li") has been appointed as the chief executive officer of Genmao (Shenzhen) Biotechnology Co. Ltd. ("Genmao Biotech"), a wholly-owned subsidiary of the Company, responsible for the strategic planning, business expansion, and daily operational management of the company with effect from 12 March 2025. Mr. Li is a senior expert in the acer truncatum industry. He has been engaged in the entire industrial chain of acer truncatum for 22 years and has rich management experience. Mr. Li has been deeply involved in the formulation of the National Standard for Acer Truncatum Bunge Seed Oil (GB/T37748-2019) and has participated in the implementation of various national-level acer truncatum industry integration projects. The Board believes that Mr. Li's professional qualifications, industry resources and management capabilities are highly consistent with Genmao Biotech's strategic direction of focusing on the development of the entire industrial chain of acer truncatum. Such appointment will significantly enhance the Company's technological barriers and brand influence in the functional food and oil market, creating long-term value for shareholders.
お知らせ • Feb 18China Health Technology Group Holding Company Limited to Report First Half, 2025 Results on Feb 28, 2025China Health Technology Group Holding Company Limited announced that they will report first half, 2025 results on Feb 28, 2025
お知らせ • Dec 05China Health Technology Group Holding Company Limited, Annual General Meeting, Dec 30, 2024China Health Technology Group Holding Company Limited, Annual General Meeting, Dec 30, 2024, at 15:30 China Standard Time. Location: unit no. 2808-10 on 28th floor, west tower shun tak centre, nos. 168-200 connaught road central, Hong Kong
お知らせ • Sep 17China Health Technology Group Holding Company Limited to Report Fiscal Year 2024 Results on Sep 30, 2024China Health Technology Group Holding Company Limited announced that they will report fiscal year 2024 results at 9:30 AM, China Standard Time on Sep 30, 2024
お知らせ • Feb 20China Health Technology Group Holding Company Limited to Report Second Half, 2023 Results on Feb 29, 2024China Health Technology Group Holding Company Limited announced that they will report second half, 2023 results on Feb 29, 2024
お知らせ • Feb 01China Health Technology Group Holding Company Limited Announces Executive ChangesThe board of directors of China Health Technology Group Holding Company Limited announced that Mr. Ngai Tsz Hin Michael ("Mr. Ngai") has tendered his resignation as the joint company secretary of the Company (the "Company Secretary") and ceased to act as an authorised representative of the Company (the "Authorised Representative") under Rule 3.05 of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") with effect from 31 January 2024. The Board also announced that, following the resignation of Mr. Ngai, Mr. Chan Ngai Fan ("Mr. Chan"), the existing company secretary of the Company, will continue to act as the Company Secretary and Mr. Chan has been appointed as the Authorised Representative with effect from 31 January 2024. Following the change, the Authorised Representatives are Professor Fei Phillip and Mr. Chan.
お知らせ • Jan 30China Health Technology Group Holding Company Limited Announces Resignation of Chan Wai Lung as an Executive DirectorChina Health Technology Group Holding Company Limited announced that Mr. Chan Wai Lung has resigned as an executive Director with effect from 29 January 2024 due to his other business engagements requiring more of time.
お知らせ • Nov 22+ 1 more updateChina Bozza Development Holdings Limited Announces CEO ChangesChina Bozza Development Holdings Limited announced Following the retirement of Mr. Li Wenjun as an executive Director, the Board announced that Mr. Li has resigned as the chief executive officer of the Company with effect from 21 November 2023. The Board announced that Mr. Chan Wai Lung ("Mr. Chan") has been appointed as the Chief Executive Officer with effect from 21 November 2023. Mr. Chan Wai Lung, aged 42, was appointed as an independent non-executive Director on 19 May 2023 and re-designated as an executive Director on 14 August 2023. Mr. Chan has years of experience in business planning and development. Mr. Chan has been an executive Director of Finsoft Financial Investment Holdings Limited since June 2017 and has been the Chief Executive Officer of Finsoft since December 2021. Mr. Chan has been a director of Draco International Investment (Holdings) Limited (specialising in designing corporate structures) since July 2013, and a director of Draco Human Resources Management Limited since November 2016. Mr. Chan was a non-executive director of Noble Engineering Group Holdings Limited from August 2018 to January 2020. Mr. Chan was appointed as a business development consultant by the Management Committee of the Haining Economic Development Zone, Zhejiang Province, the PRC in April 2017. In October 2017, he obtained his Honorary Doctorate in Business Administration from Sabi University. In November 2019, Mr. Chan completed a postdoctoral research project at California State University Monterey Bay.
お知らせ • Oct 31China Bozza Development Holdings Limited, Annual General Meeting, Nov 21, 2023China Bozza Development Holdings Limited, Annual General Meeting, Nov 21, 2023, at 15:30 China Standard Time. Location: Unit No. 280810 on 28th Floor of West Tower Shun Tak Centre Nos. 168200 Connaught Road Central, Hong Kong Hong Kong Agenda: To receive, consider and adopt the audited financial statements, the report of the directors (the "Directors") and the report of the independent auditor for the eighteen months ended 30 June 2021; to receive, consider and adopt the audited financial statements, the report of the Directors and the report of the independent auditor for the year ended 30 June 2022; to receive, consider and adopt the audited financial statements, the report of the Directors and the report of the independent auditor for the year ended 30 June 2023; and to consider other matters.
お知らせ • Sep 22China Bozza Development Holdings Limited to Report Fiscal Year 2023 Results on Sep 30, 2023China Bozza Development Holdings Limited announced that they will report fiscal year 2023 results on Sep 30, 2023
お知らせ • Sep 09China Bozza Development Holdings Limited (SEHK:1069) entered into equity sale and purchase agreement to acquire 52% stake in Liuba County Jiashisen Traditional Chinese Medicine Comprehensive Development Company Limited from Shaanxi Jiashisen Pharmaceutical Investment Company Limited for CNY 7.1 million.China Bozza Development Holdings Limited (SEHK:1069) entered into equity sale and purchase agreement to acquire 52% stake in Liuba County Jiashisen Traditional Chinese Medicine Comprehensive Development Company Limited from Shaanxi Jiashisen Pharmaceutical Investment Company Limited for CNY 7.1 million on August 16, 2023. Upon the Completion, China Bozza Development will hold 52% equity interest in Liuba County Jiashisen Traditional Chinese Medicine Comprehensive Development, which will become a non-wholly owned subsidiary of the China Bozza Development.
お知らせ • Aug 17China Bozza Development Holdings Limited Announces Board ChangesThe board (the "Board") of directors (the "Director(s)") of China Bozza Development Holdings Limited (the "Company", and together with its subsidiaries, the "Group") announced that Mr. Chan Wai Lung ("Mr. Chan"), an independent non-executive Director, has been re-designated as an executive Director with effect from 14 August 2023. Mr. Chan Wai Lung, aged 42, was appointed as an independent non-executive Director on 19 May 2023. Mr. Chan has years of experience in business planning and development. Mr. Chan has been an executive Director of Finsoft Financial Investment Holdings Limited since June 2017 and has been the Chief Executive Officer of Finsoft since December 2021. Mr. Chan has been a director of Draco International Investment (Holdings) Limited (specialising in designing corporate structures) since July 2013, and a director of Draco Human Resources Management Limited since November 2016. Mr. Chan was a non-executive director of Noble Engineering Group Holdings Limited, from August 2018 to January 2020. Mr. Chan was appointed as a business development consultant by the Management Committee of the Haining Economic Development Zone, Zhejiang Province, the PRC in April 2017. In October 2017, he obtained his Honorary Doctorate in Business Administration from Sabi University. In November 2019, Mr. Chan completed a postdoctoral research project at California State University Monterey Bay. The Board also announced that (i) Mr. Chau Wing Nam ("Mr. Chau") has been appointed as an independent non-executive Director, the chairman of the audit committee of the Company (the "Audit Committee") and the chairman of the Remuneration Committee; and (ii) Ms. Bu Xue has been appointed as an independent non-executive Director and a member of each of the Audit Committee, the Remuneration Committee and the nomination committee of the Company (the "Nomination Committee") with effect from 14 August 2023. Mr. Chau Wing Nam, aged 35, obtained his Bachelor's degree in Accounting and Accounting Technologies from the Curtin University of Technology in August 2012. He has been a member of Hong Kong Institute of Certified Public Accountants since May 2017. He has over ten years of experience in auditing, accounting and corporate management and is currently responsible for corporate finance, mergers and acquisitions matters, investors relations, corporate governance as well as compliance affairs. Mr. Chau is currently a manager of Ample Capital Limited and is a licensed person registered under the Securities and Futures Ordinance to carry out Type 6 (advising on corporate finance) regulated activity. Mr. Chau is currently an independent non-executive director of K Group Holdings Limited since June 2022 and an independent non-executive director of Mobile Internet (China) Holdings Limited since February 2023. Ms. Bu Xue, aged 34, obtained her Bachelor's degree in Business Administration from Zhengzhou University of Aeronautics in July 2011. She has attained the accounting professional qualification issued by Ministry of Human Resources and Social Security and Ministry of Finance of the People's Republic of China since September 2020 and has attained the qualification of tax advisor issued by The China Certified Tax Agents Association since December 2022. She has over ten years of experience in marketing and business development. The Board also announced that, following the change in the composition of the Board and with effect from 14 August 2023: Mr. Liu Zhaoxiang ceased to be a member of the Audit Committee; Ms. Wong Hoi Ying ceased to be the chairman of the Nomination Committee and a member of each of the Audit Committee and the Remuneration Committee; Professor Fei Phillip ceased to be a member of each of the Remuneration Committee and Nomination Committee; Mr. Wang Yibin has been appointed as a member of the Nomination Committee; Mr. Guo Zhonglong has been appointed as the chairman of the Nomination Committee and a member of the Remuneration Committee and has been re-designated as a member of the Audit Committee; Mr. Chan ceased to be the chairman of the Remuneration Committee and a member of each of the Audit Committee and Nomination Committee; Mr. Chau has been appointed as the chairman of the Audit Committee and the chairman of the Remuneration Committee; and Ms. Bu has been appointed as a member of each of the Audit Committee, the Remuneration Committee and the Nomination Committee.